Serology Testing Market Size, Share, Forecast Report 2026 to 2035

What is Serology Testing Market Size?

Global Serology Testing Market Size is valued at USD 17.13 Bn in 2025 and is predicted to reach USD 33.69 Bn by the year 2035 at a 7.2% CAGR during the forecast period for 2026 to 2035.

Serology Testing Market Size, Share & Trends Analysis Distribution by Product (Reagents & Consumables, Instruments, Software & Services), By Service (Infectious Disease Serology, Autoimmune Disease Serology, Allergy Serology, Immunohematology Serology, Transplantation & Histocompatibility Serology, Other Clinical Serology Testing), By Format (Laboratory-Based Serology Testing, Rapid Point-of-Care Serology Testing), By Technology (Chemiluminescent Immunoassay, Enzyme Immunoassay, Fluorescence-Based Immunoassay, Immunofluorescence Assay, Rapid Immunochromatographic Assay, Agglutination-Based Assay, Immunoblot & Line Immunoassay, Multiplex Bead & Array-Based Immunoassay, Other Commercial Serological Technologies), By End Use (Hospitals & Hospital-Based Laboratories, Independent Diagnostic & Reference Laboratories, Blood Banks, Blood Centres & Transfusion Laboratories, Public Health & Government Laboratories, Physician Offices, Clinics & Point-of-Care Facilities, Other End Users) and Segment Forecasts, 2026 to 2035.

Serology testing involves the examination of blood serum or plasma in order to detect antibodies, antigens, and other biomarkers related to the immune system which are connected with infectious diseases, autoimmune disorders, the immune response, and certain clinical conditions. It is employed for determining whether or not there has been previous or ongoing exposure to pathogens, for assessing the state of the immune system, to aid in diagnosis, to evaluate the response to vaccination, and to help with disease surveillance. The various serological techniques commonly used include enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), immunofluorescence assays (IFA), agglutination tests, rapid diagnostic tests, and other automated immunoassay systems used in hospitals, diagnostic laboratories, blood banks, and public health facilities.

The market for serology testing includes analyzers, instruments, assay kits, reagents, consumables, and rapid testing solutions which are used for serological analysis in both clinical and laboratory environments. It involves a range of applications such as testing for infectious diseases, blood screening, testing for autoimmune conditions, testing related to transplantation, and the assessment of immunity, and this market encompasses both centralized laboratory systems and decentralized point-of-care options. The major companies in the market compete on the basis of their assay portfolio, diagnostic accuracy, automation, throughput, regulatory approvals, workflow integration, and geographic availability, and as a result serology testing has become a significant part of the wider in-vitro diagnostics industry. 

Competitive Landscape

Which are the Leading Players in the Serology Testing Market?

• F. Hoffmann-La Roche Ltd 
• Abbott Laboratories 
• Danaher Corporation 
• QuidelOrtho Corporation 
• Bio-Rad Laboratories, Inc. 
• Grifols, S.A. 
• Siemens Healthineers AG 
• bioMérieux SA 
• DiaSorin S.p.A. 
• Thermo Fisher Scientific Inc.

Market Dynamics

Driver

Rising Prevalence of Infectious Diseases 

The growing incidence of infectious diseases is a key factor in boosting the serology testing market, since it increases the demand for reliable diagnostic methods that can detect infections and evaluate immune responses. The ongoing impact of diseases including HIV, hepatitis, dengue, and various other viral and bacterial infections is leading to higher demand for serological tests in hospitals, diagnostic laboratories, and blood banks. Such tests are able to identify antibodies and antigens that are specific to a disease, thus aiding in diagnosis, screening, and disease surveillance. Moreover, the expansion of public health screening programmes, the increasing awareness of the importance of early disease detection, and the need to keep track of infection exposure are all helping to promote the use of serology testing in both clinical and public health contexts. The rise in international travel and population movement also adds to the requirement for effective infectious disease surveillance and screening. Because healthcare systems are focusing on achieving timely diagnosis and better disease management, demand for serological testing is expected to go up. 

Restrain/Challenge

Risk of False-Positive and False-Negative Results 

A major challenge in the serology testing market is the possibility of both false-positive and false-negative results, since the accuracy of the tests can be influenced by cross-reactivity, variations in immune responses, and the time at which the sample is collected. It can take several days or weeks for antibodies to develop after an infection, which means that false-negative results may occur if the test is carried out in the early stages of the disease. Moreover, cross-reactivity with antibodies linked to other infections or disorders can cause false-positive results, making it difficult to arrive at a correct diagnosis and affecting clinical decision-making. Because of these limitations, confirmatory testing by means of molecular or other diagnostic methods is often needed, thus raising the cost of testing and prolonging the time it takes to get results. 

Reagents & Consumables Segment is Expected to Drive the Serology Testing Market

Reagents & consumables are expected to drive the serology testing market, owing to their recurring use in diagnostic procedures and the continuous demand for test kits, antibodies, antigens, assay substrates, and other essential testing materials. Unlike instruments, which are typically purchased less frequently, reagents and consumables are required for every testing cycle and must be replenished regularly. The increasing volume of infectious disease screening, blood-donor testing, and routine diagnostic procedures across hospitals, diagnostic laboratories, and blood banks is supporting segment growth. Additionally, the introduction of new assay kits, growing adoption of automated immunoassay platforms, and continued demand for reliable and rapid diagnostic results are expected to strengthen the segment's market position. 

Allergy Serology Segment is Growing at the Highest Rate in the Serology Testing Market

Allergy serology is anticipated to see the quickest growth in the serology testing market during the forecast period. The reason for this growth is the growing prevalence of various allergic conditions, such as food allergies, allergic rhinitis, asthma, and environmental allergies, together with a higher demand for accurate diagnostic techniques that can identify specific allergens. Blood-based serological tests which measure allergen-specific immunoglobulin E (IgE) assist healthcare professionals in investigating allergic sensitization, especially in cases where skin testing is not feasible. Moreover, the expansion of diagnostic capabilities, the introduction of more advanced allergy testing assays, and the greater adoption of automated laboratory systems are all expected to contribute to growth in this segment. 

Why North America Led the Serology Testing Market?

North America holds the leading position in the global serology testing market as a result of its sophisticated healthcare infrastructure, its well-developed network of diagnostic laboratories, and the high level of acceptance of advanced diagnostic technologies. This region enjoys high healthcare spending, extensive screening initiatives for infectious diseases, and long-standing blood-donor testing procedures, all of which contribute to the steady demand for serological assays.

The significant presence of large diagnostic companies, ongoing investment in research and development, and the increasing use of automated immunoassay platforms also serve to boost market growth. Moreover, the rising awareness of the importance of early disease detection and the existence of established healthcare reimbursement systems promote the use of serology testing in hospitals, clinical laboratories, and other healthcare settings. 

Key Development

September 2026: Beckman Coulter Diagnostics, a Danaher company, is expanding its infectious disease serology portfolio on the DxI 9000 Immunoassay Analyzer. The expanded assay menu supports testing for HIV, syphilis, viral hepatitis, and other infections, helping laboratories address growing screening needs, improve diagnostic sensitivity, and manage increasing test volumes efficiently. 

Serology Testing Market Report Scope: